Trials / Completed
CompletedNCT04428788
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
A Phase 1, Multi-center, Open-label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Cc-94676 in Subjects With Metastatic Castration-resistant Prostate Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 131 (actual)
- Sponsor
- Celgene · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CC-94676 | Specified dose on specified days |
| DRUG | CC1083611 | Specified dose on specified days |
| DRUG | CC1083610 | Specified dose on specified days |
Timeline
- Start date
- 2020-06-22
- Primary completion
- 2025-10-28
- Completion
- 2025-10-28
- First posted
- 2020-06-11
- Last updated
- 2025-12-22
Locations
19 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04428788. Inclusion in this directory is not an endorsement.